{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:14:49Z","timestamp":1792808089273,"version":"4.5.0"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamaoncol.2018.6737","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T21:28:43Z","timestamp":1549574923000},"page":"1049","source":"Crossref","is-referenced-by-count":203,"title":["Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Michael R.","family":"Cook","sequence":"first","affiliation":[{"name":"Department of Medicine, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown University, Washington, DC"},{"name":"Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC"},{"name":"Division of Hematology and Oncology, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"crv180011r1","first-page":"1","article-title":"Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.","volume":"48","author":"Jones","year":"1999","journal-title":"MMWR CDC Surveill Summ"},{"issue":"1","key":"crv180011r2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"crv180011r3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"crv180011r4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases.","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"crv180011r5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","article-title":"Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice.","volume":"72","author":"Mounier","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"crv180011r6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/cid\/ciu174","article-title":"Management of HIV infection in patients with cancer receiving chemotherapy.","volume":"59","author":"Torres","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"crv180011r7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/JTO.0b013e3181d3ccf2","article-title":"Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer.","volume":"5","author":"Makinson","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"6382","key":"crv180011r8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"17","key":"crv180011r9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"crv180011r10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"crv180011r11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"crv180011r12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"32","key":"crv180011r13","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1200\/JCO.2011.36.9199","article-title":"Case report: response to ipilimumab in a patient with HIV with metastatic melanoma.","volume":"29","author":"Burke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv180011r14","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.clml.2017.12.008","article-title":"HIV-related refractory Hodgkin lymphoma: a case report of complete response to nivolumab.","volume":"18","author":"Chang","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"crv180011r15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"crv180011r16","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/annonc\/mdx321","article-title":"Nivolumab in HIV-related non\u2013small-cell lung cancer.","volume":"28","author":"Hentrich","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"crv180011r17","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/annonc\/mdx538","article-title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.","volume":"28","author":"Heppt","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"crv180011r18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab.","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"issue":"6","key":"crv180011r19","doi-asserted-by":"publisher","first-page":"E540","DOI":"10.21037\/jtd","article-title":"Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer.","volume":"9","author":"McCullar","year":"2017","journal-title":"J Thorac Dis"},{"issue":"7","key":"crv180011r20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non\u2013small cell lung cancer.","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J Thorac Oncol"},{"key":"crv180011r21","first-page":"946392","article-title":"A patient with HIV treated with ipilimumab and stereotactic radiosurgery for melanoma metastases to the brain.","volume":"2013","author":"Ruzevick","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"crv180011r22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-017-0252-3","article-title":"Nivolumab as salvage treatment in a patient with HIV-related relapsed\/refractory Hodgkin lymphoma and liver failure with encephalopathy.","volume":"5","author":"Sandoval-Sus","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"crv180011r23","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/jdv.2018.32.issue-1","article-title":"Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.","volume":"32","author":"Tomsitz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"crv180011r24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma.","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"crv180011r25","first-page":"737389","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV.","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"issue":"5","key":"crv180011r26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2018.36.5_suppl.63","article-title":"HIV-positive Kaposi sarcoma and immune checkpoint blockade.","volume":"36","author":"Galanina","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv180011r27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2018.36.5_suppl.136","article-title":"Safety and efficacy of checkpoint inhibition (CI) in cancer patients (pts) with concurrent human immunodeficiency virus (HIV) infection.","volume":"36","author":"Park","year":"2018","journal-title":"J Clin Oncol"},{"key":"crv180011r30","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx376.013","article-title":"PD immunotherapy in patients with concurrent solid organ transplant, HIV, and hepatitis B and C.","volume":"28","author":"Rai","year":"2017","journal-title":"Ann Oncol"},{"issue":"33","key":"crv180011r31","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv180011r32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"crv180011r33","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"crv180011r34","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"crv180011r35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2018.06.028","article-title":"Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.","volume":"123","author":"Scilla","year":"2018","journal-title":"Lung Cancer"},{"issue":"7","key":"crv180011r36","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","article-title":"Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy.","volume":"3","author":"Yanik","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"crv180011r37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","article-title":"Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options.","volume":"12","author":"Velu","year":"2015","journal-title":"Retrovirology"},{"issue":"2","key":"crv180011r38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/QAI.0b013e3181fbab9f","article-title":"Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1\u2013infected patients on treatment.","volume":"56","author":"Grabmeier-Pfistershammer","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"crv180011r39","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency.","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"issue":"3","key":"crv180011r40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.4049\/jimmunol.1701551","article-title":"Immune checkpoint blockade restores HIV-specific CD4 T cell help for NK cells.","volume":"201","author":"Porichis","year":"2018","journal-title":"J Immunol"},{"key":"crv180011r42","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx376.068","article-title":"1208TiPA phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors.","volume":"28","author":"Gonzalez-Cao","year":"2017","journal-title":"Ann Oncol"},{"key":"crv180011r43","doi-asserted-by":"publisher","first-page":"TPS2597-TPS","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2597","article-title":"AMC 095 (AIDS Malignancy Consortium): a phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).","volume":"36","author":"Rajdev","year":"2018","journal-title":"J Clin Oncol"},{"key":"crv180011r28","author":"Samri","year":"2017"},{"key":"crv180011r29","author":"Uldrick","year":"2017"},{"key":"crv180011r41","unstructured":"ClinicalTrials.gov. Immunotherapy by nivolumab for HIV+ patients (CHIVA2). Updated February 19, 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03304093. Accessed Janury 4, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/7\/1049\/17712520\/jamaoncology_cook_2019_rv_180011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T15:02:44Z","timestamp":1562857364000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.6737"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.6737","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}